DDL Conference Chair
Dr Gary Pitcairn is currently Senior Director, Pharmaceutical Technology and Development at AstraZeneca, and is responsible for the CMC aspects of projects across both the early and late phase respiratory portfolio. Gary previously held senior positions at Mylan Pharmaceuticals and Pfizer, focusing on developing new inhaled drug products. Prior to joining Pfizer, Gary spent 15 years working at Pharmaceutical Profiles, evaluating drug delivery from a wide range of pulmonary and nasal drug delivery devices in both in vitro studies and early clinical studies.
Gary holds a BSc (Hons) in Biological Chemistry and a PhD in Pharmaceutical Sciences from the University of Nottingham and has published over 40 peer reviewed papers. Gary has been a member of the organizing committee for Drug Delivery to the Lungs (DDL) for 11 years, and has been the conference Chair for the last five years.
Imperial College London
DDL Conference Vice Chair
Dr. Omar S Usmani, MBBS PhD FHEA FRCP,
Clinical Senior Lecturer & Consultant Physician in Respiratory & Internal Medicine,
National Heart and Lung Institute (NHLI), Imperial College London & Royal Brompton Hospital
Omar Usmani leads the Clinical Research Group within the Airway Disease Section at NHLI. His clinical research is focussed on asthma, chronic obstructive pulmonary disease (COPD) and chronic cough. His research disciplines are in inhaled drug delivery, lung imaging, small airways pathophysiology, respiratory pharmacology, and digital respiratory health.
He is Vice-Chair of Drug Delivery to the Lungs (DDL), a Board member of International Society of Aerosols in Research (ISAM), and a steering committee member of the Small Airways Working Group of the World Allergy Organization (WAO). He is also Associate Editor to the journal Respiration and on the Editorial Board of COPD: Journal of the COPD Foundation.
In 2012, Dr Usmani was awarded a UK National Institute for Health Research (NIHR) Career Development Fellowship to investigate the lung deposition of inhaled bronchodilator aerosols of different particle size within the airways of patients with COPD. This is the first time this award category was been given to Respiratory Science research in the UK.
He is currently clinical lead and co-PI at Imperial College on a highly prestigious EU Horizon 20-20 consortium project, myaircoach, focussing on the role of tele-monitoring and e-health in asthma self-management, where the proposal was ranked 4th highest of all 256 submissions to the call.
In 2015, he was awarded one of the highest accolades in aerosol science, the Thomas T Mercer Award from the American Association of Aerosol Research (AAAR) and ISAM, recognising his international research excellence in pharmaceutical aerosols and inhalable materials.
Aerosol Society Treasurer
Mark has been part of the DDL organising committee since 2003 and has also been treasurer for the Aerosol Society for the past 5 years.
DDL Conference Organiser
Sheila joined The Aerosol Society in 2007 as the Society’s Administrator following many years with The Institute of Chartered Accountants in England & Wales.
Sheila has worked closely with the Aerosol Society and DDL Committees to develop the wide ranging Events offered to its membership and more recently has focused entirely on the DDL Conference helping to increase the audience and exhibitor participation from across the World.
DDL Conference Organiser
Nikki has worked for The Aerosol Society since February 2014. She began as the societies administrator, organising the Fundamentals of Science training day, the Annual Aerosol Science Conference and various Focus Meetings as well as handling the membership of the society and supporting Sheila Coates with the DDL Conference organisation. In 2015 Nikki handed the main society administration over to Sonia Mills and began focusing only on the DDL Conference organisation.
Nick Childerhouse, Associate Director – Pharmaceutical Technology, Vectura
After graduating from Waikato University (New Zealand), Nick commenced his career in the pharmaceutical industry in 1996 at Douglas Pharmaceuticals in Auckland. Following a move to the UK he entered the inhalation field at the then GlaxoWellcome in 1998. Within Glaxo Manufacturing Services, Nick held a succession of analytical roles before moving to the Innovata Biomed R&D organisation based in Nottingham in 2004. As Group Head at Innovata, Nick worked on a range of novel and generic dry powder inhaler development programmes. Following the acquisition of Innovata by Vectura Ltd in 2007, Nick moved to Vectura at Chippenham where he currently holds the position of Associate Director – Pharmaceutical Technology. In this role, Nick is responsible for the development of novel particle engineering, formulation and processing technologies along with improving understanding of related device interactions and associated analytical techniques including more realistic in-vitro testing techniques.
DPDD – Drug Product Design & Development - WR RD Product Development & Supply
A qualified pharmacist, after completing her PhD from University of Cardiff in 1997 on the re-formulation of MDIs in novel hydrofluoroalkanes, Michelle started her industrial career developing dry powder inhalers at Novartis Horsham Research Centre (UK). She moved to GlaxoSmithKline R&D in 1999 where she has since led the formulation development of a number of dry powder inhaler products, from Phase 2b to launch and post launch commitments. She has significant experience in both formulation and process development to QbD principles, technology transfer and regulatory interaction, and applies her technical acumen and experience in leading scientific understanding initiatives within the department.
King's College London
Ben Forbes is Professor of Pharmaceutics at King’s College London. He has a BPharm from King’s College London (1987) and a PhD in Drug Delivery from Strathclyde University (1996). Before doctoral studies, he worked in hospital pharmacy in London and Sydney, and for Inveresk Clinical Research in Edinburgh. Professor Forbes was appointed to the academic staff of King’s College London in 1997. He is a registered pharmacist in the UK. He originated the term ‘Inhalation biopharmaceutics’ to describe the factors that influence the rate and extent of drug absorption from the lungs and has authored many publications in this area, including: (1) inhaled medicine formulation, (2) the development and application of techniques to study respiratory drug transport and metabolism, (3) respiratory toxicology/disease. He is founder and coordinator of the APSGB ‘Drug Delivery to the Lungs’ Network, a UK-based international academia-industry-regulatory group dedicated to pre-competitive collaboration: http://www.apsgb.org/drugsinthelungs/
Leading Respiratory Drug Delivery
David leads the Respiratory Drug Delivery sector at PA Consulting and enjoys the challenge of balancing commercial and technical activities.
“One of the best things about working at PA is being surrounded by like-minded and intelligent people – many of whom are leaders in their field. Drug delivery is a hugely exciting sector to work in and it offers a wide range of technical and scientific challenges. It’s also very rewarding – the products that we and others like us develop have the potential to massively improve people’s lives. It’s a great pleasure working with clients who share these aspirations.”
David is a physicist and has been working in the field of medical device development since 1994, where he started his career in the Respiratory Physics group at Fisons. He specialises in respiratory drug delivery and enjoys applying solid aerosol science and fluid dynamics to improve the efficacy of inhaler technology. David has numerous patents and publications in this area and regularly presents at conferences.
Ph.D., B.Sc (Hons)
Phil Haywood is a consultant in inhalation and intranasal product development. He works with large pharmaceutical, device and small biotech companies assisting with CMC aspects of their pulmonary product development programmes.
Previously head of Inhalation and Device Development department at Novartis from 2002 to 2005 responsible for inhalation product development.
He also worked for 28 years at GSK in pharmaceutical and respiratory product development in increasing roles of seniority including head of Respiratory Analysis, Analytical Research 2, Clinical Supplies UK and Inhalation Product Development UK departments.
At GSK, he worked for over 15 years in inhalation product development and was a senior member in the GSK inhalation development departments during the CFC/HFA transition and the development of Servent, Flovent and Seretide/Advair in both MDI and DPI formats.
At both GSK and Novartis he was part of or led teams developing their inhalation and intranasal products and sat on senior strategy and research boards.
He has been a member of IPAC-RS and now serves on the DDL organising committee.
He obtained his PhD via CNAA through the University of Hertford and his BSc from the University of London.
Yorick Kamlag, is Head RIA CMC projects, Pharmaceutical Sciences at AstraZeneca. In this role he is responsible for the CMC aspects of projects in the early phase respiratory portfolio.
He previously held several positions at Vectura and Zentiva were he was responsible for design and development of robust formulation / manufacturing / analytical processes and technologies of several inhalation products.
He has previously been chair of EPAG and has been a member of the DDL organizing committee for 5 years.
Prof. Dr. Regina Scherließ (*1979) is a pharmacist and did her PhD in 2008 on “Formulation of inhalation combination products by co-precipitation”. She then started her own research group working on “Formulations for mucosal vaccination” in the Department of Pharmaceutics and Biopharmaceutics at Kiel University, Germany. During her work she performed research stays in the US, New Zealand and Australia. She received several young researcher awards including The Pat Burnell New Investigator Award 2010 and finished her “Habilitation” in 2015. Her research interests include disperse systems and nanoparticles, stabilization of biomolecules in spray drying and formulations for mucosal vaccination with a focus on respiratory (nasal and pulmonary) dry powder delivery. Since September 2017 she is professor for Pharmaceutics and Biopharmaceutics and chair of the Department of Pharmaceutics at Kiel University. As such she heads the research unit in Pharmaceutics and is responsible for all teaching in Pharmaceutics and Biopharmaceutics
3M Drug Delivery Systems Division
Alex Slowey is a pharmacist with nearly 20 years’ experience in the pharmaceutical industry. Since November 1997, he has held various roles within the R&D function at 3M Drug Delivery Systems, which have given him a broad footing in the pharmaceutical industry, particularly in relation to the research and development activities required to get new products from initial feasibility to registration.
Alex is specialised in early phase development activities related to the formulation of new and existing molecules for pulmonary and nasal delivery. He has expertise in a number of key areas, including providing technical and project leadership to development programmes.
Alex’s interests include the formulation of pMDIs using innovative approaches, and particle engineering, with direct application to the delivery of molecules via the pulmonary and nasal routes. He also has clinical expertise, particularly with respect to PK/PD studies of pMDIs
Director, Scientific Affairs, Aptar Pharma, Prescription Division, France
After obtaining his Ph.D. from the University of Wales, UK in 1985, he has held various industrial positions at Monsanto Inc. (UK), Fisons Ltd (UK), Valois (France) and Inhale/Nektar Therapeutics (USA).
He is now in charge of scientific affairs for the Aptar Pharma Prescription division, Le Vaudreuil, France and is engaged in the development of new devices for nasal, inhaled and injectable drug products.
University of Parma
Dr. Francesca Buttini is currently holding an Assistant Professor position at the Department of Pharmacy and Food Science, University of Parma (IT) leading the unit dedicated to the development of product for inhalation. In 2014, she was appointed as Visiting Lecturer in the Institute of Pharmaceutical Science of King’s College London (UK) and affiliated as Key Researcher at the Research Center Pharmaceutical Engineering (Graz, AT). In 2003 she obtained an MSc in Pharmacy at the School of Pharmacy of the University of Parma and in 2007 she received a PhD dregree in Biopharmaceutics-Pharmacokinetics. Her main research area is the formulation and testing of dry powder inhalers. She is an expert on particle engineering using a QbD approach, dissolution test of microparticles and characterization of device-formulation combination. Up to date, Francesca has published 37 original papers, 5 book chapters and 4 patents on drugs and drug delivery systems. Finally, she is a co-founder of Plumestars, an innovative startup focused on the development of product to treat lung diseases.
University of Otago
Dr Shyamal Das is a Senior Lecturer in Pharmaceutical Science at the University of Otago since 2013. He pursued a Research Fellowship at Monash Institute of Pharmaceutical Sciences after obtaining his PhD degree from the same Institute in 2009. He also received research training at the Imperial College of London, the University College of London and the University of Sydney. He also worked in a pharmaceutical industry after his undergraduate degree in pharmacy.
Dr Das leads the research on pulmonary drug delivery of powders in New Zealand. His particular interests are (i) Solid surface characterization for understanding powder behaviour (ii) Particle engineering approaches (eg, spray drying, dry coating, crystallization and milling) to develop efficient and stable powder formulations, (iii) Dissolution of drugs in the lung and subsequent absorption and toxicity. He has published many papers and presented in >50 conferences on fundamental understanding in these areas.
Dr Das has been successful in receiving grants and fellowships as principal applicant including the prestigious nationally competitive grant from Health Research Council of New Zealand and grants from pharmaceutical industries. He has established collaboration with several established research groups worldwide. He has examined PhD theses from Australia, New Zealand, Asia and the UK (eg, Imperial college of London) and consulted to Pharmaceutical industries.
Dr Das is also a passionate teacher. He won the OUSA 2016 Teaching Excellence Award -Top Five Teacher 2016
The University of New Mexico
Dr. McConville is an Associate Professor in the Department of Pharmaceutical Sciences at the University of New Mexico and an Adjunct Professor in the Department of Pharmaceutical Technology at the University of Bonn. He earned an Applied Chemistry degree from the University of Coventry in 1994, before working as a researcher in the field of aerosol drug delivery at the University of Bath, in the Centre for Drug Formulation Studies (CDFS). In 1999, he moved to Scotland and received his Ph.D. at the University of Strathclyde in 2002, working on chronopharmaceutical drug delivery. He then worked as a post-doctoral fellow at the University of Texas at Austin, before later being appointed to the rank of an Assistant Professor in 2006. Here his work was centered on administration of antifungals and cancer chemotherapy agents, via inhalation. Dr. McConville joined the faculty at the University of New Mexico in 2012, and his current research interests focus on using new technologies to improve patient compliance and health outcomes with inhalation, oral, and thin film delivery technologies. Dr. McConville serves as the Associate Editor of Special and Themed Editions for Drug Development and Industrial Pharmacy, on the Editorial Advisory Board of Inhalation, and the Journal of Biopharmaceutics and Therapeutic Challenges, and as a Scientific Advisor for the International Pharmaceutical Excipients Council of the Americas.
Jolyon Mitchell Inhaler Consulting Services Inc
Dr. Jolyon Mitchell, PhD, FRSC (UK), CChem. CSci, is the CEO of Jolyon Mitchell Inhaler Consulting Services Inc., specializing in the laboratory evaluation of all types of orally inhaled products (OIPs). He was formerly Scientific Director of Trudell Medical International, a company manufacturing devices for delivering inhaled medications. His interests include all aspects of laboratory testing of inhalers, including the development of methods that mimic patient use. In the role of Scientific Adviser to the International Pharmaceutical Consortium on Regulation and Science (IPAC-RS), he has helped pioneer simplified but powerful methods for determining aerodynamic size-related parameters of importance for inhaler-generated aerosols through the Abbreviated Impactor Measurement (AIM) and Efficient Data Analysis (EDA). He also has an active role in EPAG, currently participating in their CFD and Device Resistance sub-team. He played a major part in standards development for ISO 20072:2009, ISO 27427:2010, and CAN/CSA Z264.1-02:2002 (rev. 2008). He was appointed to the 2010-2015 and 2015-2020 sessions of the USP Expert Committee: General Chapters – Dosage Forms, and currently co-chairs the Aerosols subcommittee. He is an adjunct professor at the University of Western Ontario and an affiliate professor at University of Hawaii. He is on the Editorial Advisory Board for Inhalation, has published more than 400 articles and contributed to five books relating to aerosol technology and inhaler products in particular.
University of Hertfordshire
Darragh is theAssociate Dean for Enterprise in the School of Life and Medical Sciences at the University of Hertfordshire, where he also carries out his research in the Centre for Topical Drug Delivery and Toxicology (TDDT). He trained as a pharmacist initially, gaining a BSc. (Pharm.) from Trinity College Dublin and then a PhD in Pharmaceutical Technology from King’s College London.
Darragh’s research focuses on improving drug delivery products for topical administration of medicines to patients, particularly for inhaled aerosol therapies. In TDDT the research collaborations revolve around developing an understanding of how inhalable particles can be manufactured and processed such that a stable formulation and product can be developed. Through academic and industrial collaboration, he also investigates the factors affecting on-demand generation of a therapeutic aerosol by the patient. This involves assessment of the biological exposure behaviour and responses after inhalation, and the development of advanced analytical techniques to assess product performance and use by patients.
Steve Newman is a Scientific Consultant based in Norfolk, UK. He has a BA in Physics from the University of Oxford (1971), an MSc in Radiation Physics from the University of London (1974), and a PhD in the Faculty of Medicine of the University of London (1982). Steve was a Medical Physicist at the Royal Free Hospital, London, UK, from 1971 to 1982. From 1982 to 1991 he was a Principal Physicist and Honorary Senior Lecturer in the Department of Thoracic Medicine, Royal Free Hospital and School of Medicine, London, UK. From 1991 to 2004, Steve was a Director and Chief Scientist of Pharmaceutical Profiles, a company based in Nottingham, UK. Steve has published over 250 research papers, invited articles and book chapters. These publications are mostly concerned with aspects of pulmonary and nasal drug delivery. He has given numerous lectures both at international conferences and within the pharmaceutical industry. In 2009, he was principal author and editor of “Respiratory Drug Delivery: Essential Theory and Practice”, published by RDD Online and Virginia Commonwealth University. Steve is a Fellow of the Institute of Physics in the UK (F Inst P). He acts as a reviewer for many medical and pharmaceutical journals, and is a member of the editorial boards of the Journal of Aerosol Medicine and Pulmonary Drug Delivery, and Expert Opinion on Drug Delivery. In 2007 he received the Thomas T Mercer award, jointly presented by the International Society for Aerosols in Medicine and the American Association of Aerosol Research, for “excellence in pharmaceutical aerosols and inhalable materials”.
Dr. Steven Nichols is a Specialist Consultant OINDPs and their devices and has 30 years of industrial experience in inhaled and nasal product development.
Founder of European Pharmaceutical Aerosol Group (EPAG).
Expert Group Membership (Current and Past)
Member of the European Pharmacopoeia “Inhalanda” working group.
Member of the European Pharmacopoeia ‘HFA propellants’ working group
Member British Pharmacopoeia, Committee of Experts – Pharmacy.
Chair British Pharmacopoeia ‘Inhaled products’ working party (formed 2011)
Member of ISOTC 84/JWG 5 – Pulmonary delivery device group that developed standard ISO 20072 ‘Aerosol drug delivery device design verification – Requirements and test methods’. (activity completed).
Has made over 50 presentations at International Conferences and has many papers published in peer reviewed journals.
Research Center Pharmaceutical Engineering
Sarah Zellnitz is a pharmacist by training. During her PhD at the Graz Technical University (AT) she explored glass beads as new model carries in dry powder inhalers (DPIs) and gained expertise in particle engineering via surface modification and detailed material characterization. She currently holds the position of Senior Scientist at Area II “Advanced Products and Delivery” at the Research Center Pharmaceutical Engineering (RCPE) in Graz (AT), where she is leading the Inhalation group and coordinating the different activities in this field. Her research focus is on tailoring DPI formulations via mechanistic understanding of the interplay of material properties, formulation properties, adhesive-cohesive force balance and drug detachment.
Sarah has joined the conference abstract review panel for Drug Delivery to the Lungs (DDL) last year.